Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1011507

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential effect of delays in drug supply chains on access to medicines for breast cancer patients in the event that the UK leaves the EU without a deal.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	194155
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the unlikely the event that the UK were to leave the EU without a deal.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand medicines for breast cancer patients are vitally important to many people in this country. However, the Department recognises that through its medicines supply contingency programme, it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 194160 question first answered 28/11/2018 14:02:20 answering member 1585 label Biography information for Stephen Hammond
tabling member	4525 label Biography information for Christina Rees

1011510

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what advice he has issued to manufacturers of general sales list medicines on whether to stockpile medicines in preparation for the UK leaving the EU without a deal; whether he plans to update that advice before the end of 2018; and if he will make a statement.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	194157
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply the United Kingdom with pharmacy (P) or prescription-only medicines (POM) from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU Exit.</p><p> </p><p>Over-the-counter ‘General Sales List’ (GSL) medicines are not included in the Department’s medicines supply contingency programme. GSLs are not considered in-scope for the programme as there are multiple alternatives available should a single GSL medicine be subject to a short-term supply disruption.</p><p> </p><p>The Department is currently considering how best it may support pharmaceutical companies as part of its medicine supply contingency programme. Part of this support will include funding to provide additional capacity for the storage of P and POM medicines in the UK. A process to apply for such funding has been undertaken in recent weeks and contract agreements are imminent.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 194158 194159 question first answered 26/11/2018 16:08:43 answering member 1585 label Biography information for Stephen Hammond
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1011511

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people presenting at NHS services because they are unable to purchase general sales list medicines for (a) themselves and (b) their children in the event that the UK leaves the EU without a deal; and if he will make a statement.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	194158
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply the United Kingdom with pharmacy (P) or prescription-only medicines (POM) from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU Exit.</p><p> </p><p>Over-the-counter ‘General Sales List’ (GSL) medicines are not included in the Department’s medicines supply contingency programme. GSLs are not considered in-scope for the programme as there are multiple alternatives available should a single GSL medicine be subject to a short-term supply disruption.</p><p> </p><p>The Department is currently considering how best it may support pharmaceutical companies as part of its medicine supply contingency programme. Part of this support will include funding to provide additional capacity for the storage of P and POM medicines in the UK. A process to apply for such funding has been undertaken in recent weeks and contract agreements are imminent.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 194157 194159 question first answered 26/11/2018 16:08:44 answering member 1585 label Biography information for Stephen Hammond
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1011512

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to offer financial support to manufacturers of general sales list medicines for the stockpiling of medicines in preparation for the UK leaving the EU without a deal.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	194159
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply the United Kingdom with pharmacy (P) or prescription-only medicines (POM) from, or via, the European Union/European Economic Area (EEA), asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no deal EU Exit.</p><p> </p><p>Over-the-counter ‘General Sales List’ (GSL) medicines are not included in the Department’s medicines supply contingency programme. GSLs are not considered in-scope for the programme as there are multiple alternatives available should a single GSL medicine be subject to a short-term supply disruption.</p><p> </p><p>The Department is currently considering how best it may support pharmaceutical companies as part of its medicine supply contingency programme. Part of this support will include funding to provide additional capacity for the storage of P and POM medicines in the UK. A process to apply for such funding has been undertaken in recent weeks and contract agreements are imminent.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 194157 194158 question first answered 26/11/2018 16:08:43 answering member 1585 label Biography information for Stephen Hammond
tabling member	3972 label Biography information for Baroness Chapman of Darlington

1011513

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with pharmaceutical companies on stockpiling breast cancer medicines to prepare for the possibility of the UK leaving the EU without a deal.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	194160
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the unlikely the event that the UK were to leave the EU without a deal.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand medicines for breast cancer patients are vitally important to many people in this country. However, the Department recognises that through its medicines supply contingency programme, it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 194155 question first answered 28/11/2018 14:02:20 answering member 1585 label Biography information for Stephen Hammond
tabling member	4525 label Biography information for Christina Rees

1011524

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nurses: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the change in funding was for nursing higher education in 2016.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	194168
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>There was no change in funding for nursing higher education in 2016.</p><p> </p><p>In the Spending Review 2015 the Government announced that tuition and maintenance costs for new pre-registration nursing, midwifery and allied health degree students would be funded by the student loans system from 2017.</p><p> </p><p>Typically, students on the loan system are at least 25% better off whilst they study than the previous funding system and eligible healthcare students have access to additional non-repayable Government funding of £1,000 for childcare, funding for travel to clinical placements and an exceptional support fund of up to £3,000 per student per academic year.</p><p> </p><p>The latest University and Colleges Admissions Service (UCAS) data from October 2018 shows that demand for nursing courses remains strong, with applications exceeding available places in 2018. The number of acceptances to nursing and midwifery courses in 2018 is consistent with earlier years, at approximately 22,000.</p><p> </p><p>Final UCAS data will be published in December 2018.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 26/11/2018 16:10:03 answering member 1585 label Biography information for Stephen Hammond
tabling member	4244 label Biography information for Jonathan Ashworth

1011559

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pain: Clinics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the average waiting times have been for (a) a referral and (b) an urgent referral to a pain clinic in each clinical commissioning group area in the most recent period for which figures are available.
tabling member constituency	High Peak
tabling member printed	Ruth George
uin	194181
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>The information is not held centrally.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 26/11/2018 16:06:59 answering member 1585 label Biography information for Stephen Hammond
tabling member	4662 label Biography information for Ruth George

1011615

registered interest
date	21/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Migrants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 November 2018 to Question 191946 on Health Services: Immigrants, what the evidential basis was for his Department's conclusion that the surcharge has had no effect on recruitment and retention of NHS staff.
tabling member constituency	Cardiff Central
tabling member printed	Jo Stevens
uin	194214
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>The Government publishes quarterly updates on immigration statistics, which include data on visa grants and is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/immigration-statistics-year-ending-march-2018/why-do-people-come-to-the-uk-2-to-work" target="_blank">https://www.gov.uk/government/publications/immigration-statistics-year-ending-march-2018/why-do-people-come-to-the-uk-2-to-work</a></p><p> </p><p>The available evidence suggests that, since its introduction, there has not been any negative impact on the number of applications made to come to the United Kingdom as a result of the surcharge.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 26/11/2018 16:11:10 answering member 1585 label Biography information for Stephen Hammond
tabling member	4425 label Biography information for Jo Stevens